STOK

26.7500.67%
IA

Isabel Aznarez

Co-Founder & CTO

Ms. Isabel Aznarez, Ph.D., is a Co-Founder of Stoke Therapeutics, Inc. and was its Head of Research and Senior Vice President since 2024 until July 2026 and serves as its CTO since July 2026. She was Senior Vice President of Discovery Research at Stoke Therapeutics, Inc. since May 2024 until 2024 and its Group Vice President of Discovery Research since 2021 also its Vice President, Head of Biology until 2021. Ms. Isabel has an extensive experience in human genetics, RNA metabolism and modulation of RNA processes using antisense oligonucleotides. Prior to founding Stoke Therapeutics, she was a research investigator with Professor Adrian Krainer, whose lab she joined as a postdoctoral fellow in 2008. Previously, she was a researcher at the Hospital for Sick Children with Professor Lap-Chee Tsui, where she focused on the effect of cystic fibrosis mutations on the splicing of the CFTR gene. She holds a Ph.D. in medical and molecular genetics from the University of Toronto and a B.Sc. in biology and human genetics from the University of Uruguay.

Positions